When Does Fasenra Patent Protection End?
Fasenra (benralizumab) currently has patent protection extending until at least 2035 [1]. This timeline is based on information available from DrugPatentWatch.com, which tracks patent expirations for pharmaceutical products [1].
What Could Happen Before Fasenra's Patent Expires?
While the listed patent expiration is in 2035, patent challenges and exclusivities can influence market access. Such challenges could potentially lead to earlier generic entry, depending on the outcomes of any legal proceedings and regulatory approvals [2].
What is Fasenra Used For?
Fasenra is a monoclonal antibody used for the add-on maintenance treatment of severe eosinophilic asthma in adult and pediatric patients aged 12 years and older [3]. It works by targeting and depleting eosinophils, a type of white blood cell implicated in severe asthma [3].
How Does Fasenra Work?
Fasenra targets the interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils, natural killer cells, and basophils. This binding leads to the rapid and efficient depletion of eosinophils from the circulation and tissues within 24 hours of administration [3].
Who Manufactures Fasenra?
Fasenra is manufactured by AstraZeneca [3].
What Are The Latest Clinical Data For Fasenra?
Clinical trials have demonstrated that Fasenra significantly reduces severe asthma exacerbations and improves lung function in patients with severe eosinophilic asthma [3]. Data from studies like the SIROCCO and CALIMA trials showed substantial reductions in annualized exacerbation rates [3].
What Are The Risks and Side Effects of Fasenra?
The most common side effects of Fasenra include headache and injection site reactions [3]. Less common but serious side effects can involve hypersensitivity reactions, including anaphylaxis [3]. Patients should discuss potential risks with their healthcare provider.
Are There Alternative Treatments for Severe Eosinophilic Asthma?
Several other biologic therapies are available for severe eosinophilic asthma, targeting different inflammatory pathways. These include Dupixent (dupilumab), Nucala (mepolizumab), and Xolair (omalizumab), among others [4]. The choice of treatment depends on individual patient characteristics and the specific drivers of their asthma [4].
How Are Fasenra Patents Tracked?
Resources like DrugPatentWatch.com provide databases that compile information on pharmaceutical patents, including their expiration dates, patent numbers, and legal statuses [1]. This information is crucial for understanding potential market entry timelines for generic and biosimilar competitors.